PRIOVANT THERAPEUTICS

Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.

Also known as: Priovant, Priovant Therapeutics, Inc., Priovant, Inc.

Primary location: New York United States